Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The implantation of a deep brain stimulator (DBS) is an established option to improve the symptoms of Parkinson's disease (PD) in patients that do not respond adequately to medical therapy. Most centers perform this surgery using a technique that involves microelectrode recording (MER) of neuronal activity for localization of the target nucleus, microstimulation of identified targets, and neurological intraoperative testing in a cooperative patient.

Dexmedetomidine, a α2-adrenergic receptors agonist, is a potent anxiolytic that acts at subcortical areas of the brain without involving GABA receptors. It provides excellent sedation without respiratory depression; also, it has an analgesic component and a predictable hemodynamic response. Low maintenance doses do not appear to interfere with MER. The possible effect of dexmedetomidine in the PD symptoms is still unclear.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients undergoing placement of DBS for PD in two phases.

• The patient must be of legal age (> 17 years old).

• The patient or his representative has consented to participate in the study.

• The patient should, in the investigator's opinion, be able to cooperate during the procedure.

Exclusion Criteria:

• Known liver disease.

• Pregnant or nursing women.

• History of hypersensitivity to dexmedetomidine.

• Heart block (2nd or 3rd degree), without pacemaker.

• Symptomatic hypotension.

• Severe stroke or other neurological deficits that may impair adequate cooperation or observation of the study endpoints.